Oncolytics Biotech (NASDAQ:ONCY) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• Oncolytics Biotech's stock has a confirmed "sell (E+)" rating from Weiss Ratings, while other analysts have varied opinions including a "buy" and "strong-buy" rating.
• The company's stock price has fluctuated between a one-year low of $0.33 and a high of $1.51, reflecting its volatility in the market.
• Oncolytics Biotech's recent quarterly earnings report showed an earnings per share (EPS) of ($0.05), exceeding analyst expectations of ($0.11).

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Several other equities analysts have also recently issued reports on ONCY. Lake Street Capital assumed coverage on shares of Oncolytics Biotech in a research report on Wednesday, August 13th. They issued a "buy" rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of Oncolytics Biotech from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Zacks Research raised shares of Oncolytics Biotech from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $5.00.

Oncolytics Biotech Price Performance

ONCY stock opened at $1.20 on Friday. The company has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $0.89. The stock has a market cap of $120.43 million, a price-to-earnings ratio of -4.44 and a beta of 1.24. Oncolytics Biotech has a 1 year low of $0.33 and a 1 year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.06. On average, equities research analysts anticipate that Oncolytics Biotech will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Oncolytics Biotech stock. Seeds Investor LLC boosted its stake in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) by 17.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 223,767 shares of the company's stock after acquiring an additional 33,826 shares during the period. Seeds Investor LLC owned 0.23% of Oncolytics Biotech worth $173,000 as of its most recent filing with the SEC. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.